JUMP70 Platform Program
ALS (Amyotrophic Lateral Sclerosis)
Key Facts
About SOLA Biosciences
SOLA Biosciences is a private, pre-clinical stage biotech targeting a high-need area in neurodegeneration through its JUMP70 RNA platform. The company's approach centers on correcting protein misfolding, a common pathological mechanism in conformational diseases such as ALS and Parkinson's disease. While still early-stage, its technology holds potential for a disease-modifying impact in markets with significant unmet medical need. The company's success will hinge on validating its platform in the clinic and securing strategic partnerships or funding to advance development.
View full company profileAbout SOLA Biosciences
SOLA Biosciences is a private, pre-clinical stage biotech targeting a high-need area in neurodegeneration through its JUMP70 RNA platform. The company's approach centers on correcting protein misfolding, a common pathological mechanism in conformational diseases such as ALS and Parkinson's disease. While still early-stage, its technology holds potential for a disease-modifying impact in markets with significant unmet medical need. The company's success will hinge on validating its platform in the clinic and securing strategic partnerships or funding to advance development.
View full company profileOther ALS (Amyotrophic Lateral Sclerosis) Drugs
| Drug | Company | Phase |
|---|---|---|
| Autologous Wnt-activated ADSC Therapy | Regeneration Biomedical | Pre-clinical |